探索生物类似胰岛素切换的利益相关者的看法和经验:一个范围审查
Ben Hindley1,2, Sally Wright1, Cheong Ooi3
1Clinical Pharmacy and Therapeutics Research Group, School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Endocrinology, diabetes & metabolism
|December 30, 2025
概括
利益相关者对生物类似胰岛素切换器的看法仍然不确定,对实际切换体验的研究有限. 需要更多的研究来指导医疗保健系统实施可接受的生物类似胰岛素切换计划.
科学领域:
- 药物经济学 药物经济学
- 医疗保健服务研究 医疗服务研究
- 内分泌学 在内分泌学.
背景情况:
- 生物类似胰岛素为参考产品提供了具有成本效益的替代品,自2014年以来,其市场份额逐渐增加.
- 利益相关者对生物类似胰岛素切换的看法和经验尚不清楚.
- 本范围审查综合了有关生物类似胰岛素开关利益相关者的观点的当前知识.
研究的目的:
- 识别和综合有关利益相关者对生物类似胰岛素开关的感知和经验的当前知识.
- 探索采用生物类似胰岛素切换的障碍和促进因素.
- 要突出有关管理生物类似胰岛素切换计划的文献上的空白.
主要方法:
- 在多个数据库 (PubMed, Web of Science, CINAHL Ultimate) 进行系统的文献搜索.
- 包括灰色文献和参考清理.
- 对符合条件的文章进行主题分析,以叙述性地综合发现.
主要成果:
- 从184个已识别的记录中,包括20个记录,包括研究,评论和意见稿.
- 医疗保健专业人员的担忧和患者的看法是采用的关键障碍,尽管大多数患者并没有强烈反对.
- 参考产品的确定的有效性和财务考虑影响了接受;也确定了转换的促进者.
结论:
- 关于利益相关者对生物类似胰岛素开关,特别是管理计划的看法存在重大不确定性.
- 有一个显着的缺乏文献详细介绍了经历过生物类似胰岛素切换的利益相关者的经验.
- 进一步的研究对于指导医疗保健系统在为专业人员和患者实施可接受的生物类似胰岛素切换计划至关重要.
相关概念视频
Drug Products: Biologics, Biosimilars and Interchangeables
208
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
208
Bioequivalence studies: Biowaivers
197
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
197
Insulin: Biosynthesis, Chemistry, and Preparation
1.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.2K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
154
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
154
Bioequivalence: Overview
1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644


